Pexxes develops affordable biologic therapies for chronic diseases in dogs, cats, and horses. By combining advanced technologies with a focus on accessibility, they aim to expand treatment options for pets worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases are increasingly prevalent in companion animals like dogs, cats, and horses, yet treatment options are often limited and expensive, hindering access to advanced veterinary care. This gap leaves many pets without adequate solutions for managing their conditions and improving their quality of life.
Solution
Pexxes is developing affordable biologic therapies to address chronic diseases in dogs, cats, and horses. By leveraging advanced technologies and strategic partnerships, Pexxes aims to create accessible and effective treatments that expand the therapeutic landscape for pets worldwide. Their approach focuses on identifying and developing high-affinity binders with exceptional biological activity and developability properties through phage display from both in vivo immunization and species-specific libraries. This enables the generation of diverse, high-affinity binders against specific targets of interest, ultimately leading to more affordable and accessible biologic therapies.
Target Audience
Pexxes' primary customers are veterinarians and pet owners seeking affordable and effective biologic therapies for chronic diseases in dogs, cats, and horses.
Features
- Antibody discovery campaigns utilizing phage display from in vivo immunization and species-specific libraries.
- Focus on generating diverse, high-affinity binders against the target of interest.
- Development of biologics for chronic diseases in dogs, cats, and horses.
- Emphasis on affordability to expand access to cutting-edge treatments.